ASH1L (Q9NR48) variants and mutations
ASH1L (also known as Q9NR48) is a human protein-coding gene encoding a histone-lysine N-methyltransferase protein. It regulates chromatin through histone methylation and helps maintain transcriptional programs during development, particularly in the nervous system. Haploinsufficiency causes an intellectual-developmental disorder frequently associated with autism, language impairment, and behavioral abnormalities. This analysis covers 3,636 ASH1L variants and mutations. Of these, 51% have computational variant effect predictions. Disease context includes intellectual disability, autosomal dominant 52, Intellectual disability, and hereditary disease. Example ASH1L variants include M1?, P3A, and N5S.
Variant analysis overview
- Gene: ASH1L
- Protein: Q9NR48
- UniProt accession: Q9NR48
- Organism: Homo sapiens
- Variants analyzed: 3636
- Variant scope: all variants
- Completed: 2026-08-20
Variant and mutation evidence
- Variant composition: 3,370 unspecified-consequence records; 1 stop lost; 80 synonymous variants; 169 missense variants; 3 stop-gained variants; 5 frameshift variants; 5 splice-region variants; 2 in-frame deletions; 1 in-frame insertions
- Prediction scores: 1,869 variants have prediction scores (51% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: intellectual disability, autosomal dominant 52, Intellectual disability, hereditary disease, neurodevelopmental disorder, syndromic complex neurodevelopmental disorder, autosomal dominant non-syndromic intellectual disability, atrial fibrillation, Neurodevelopmental delay, Abnormality of the skeletal system, autism spectrum disorder, Global developmental delay, allergic rhinitis.
Protein structure and variant hotspots
- Protein features: 5 domains; 8 post-translational modification sites.
- Structural context: 480 variants have structural context.
- PTM context: 8 variants overlap post-translational modification sites.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, gnomAD constraint, Open Targets, ClinGen, MaveDB, LitVar.
Notable ASH1L variants
Examples include M1?, P3A, N5S, T6S, A7D, A7V, M8I, M8V. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- M1?, rs756914885, NCI-TCGA Cosmic COSV6420, MetaLR 0.77, MetaSVM 0.37, Variant assessed as somatic; high impact.
- P3A (p.Pro3Ala), ExAC rs753406103, gnomAD rs753406103, REVEL 0.20, CADD 19.80
- N5S (p.Asn5Ser), TOPMed rs941197272, gnomAD rs941197272, REVEL 0.34, CADD 22.50
- T6S (p.Thr6Ser), TOPMed rs1193888970, gnomAD rs1193888970, REVEL 0.32, CADD 22.90
- A7D (p.Ala7Asp), cosmic curated COSV64206
- A7V (p.Ala7Val), gnomAD rs1338615092, REVEL 0.45, CADD 26.70
- M8I (p.Met8Ile), cosmic curated COSV64208
- M8V (p.Met8Val), ExAC rs777411239, gnomAD rs777411239, REVEL 0.47, CADD 24.20
- G10R (p.Gly10Arg), cosmic curated COSV10468, REVEL 0.49, CADD 27.10
- G12A (p.Gly12Ala), TOPMed rs1668886085
- G12R (p.Gly12Arg), ExAC rs755568171, gnomAD rs755568171, REVEL 0.51, CADD 23.30
- D14A (p.Asp14Ala), ExAC rs753297401, gnomAD rs753297401, REVEL 0.37, CADD 23.70
- D14N (p.Asp14Asn), gnomAD rs1321580908, REVEL 0.45, CADD 23.60
- S15C (p.Ser15Cys), gnomAD rs1443127886, REVEL 0.48, CADD 23.80
- E16D (p.Glu16Asp), gnomAD rs1391197337, REVEL 0.38, CADD 23.10
- E16K (p.Glu16Lys), cosmic curated COSV64207, gnomAD rs1327217540, REVEL 0.42, CADD 23.80
- G17C (p.Gly17Cys), cosmic curated COSV10819, Uncertain significance, Intellectual disability, autosomal dominant 52
- G17D (p.Gly17Asp), NCI-TCGA Cosmic COSV1008, cosmic curated COSV10085, Ensembl rs1668884567, Uncertain significance, Inborn genetic diseases
- G17S (p.Gly17Ser), NCI-TCGA Cosmic COSV1008, cosmic curated COSV10085, Uncertain significance, Intellectual disability, autosomal dominant 52
- S19* (p.Ser19Ter), cosmic curated COSV10592
- R20K (p.Arg20Lys), cosmic curated COSV64205
- K21E (p.Lys21Glu), rs2524745507, ClinGen CA342716705, ClinVar RCV002291915, REVEL 0.39, CADD 25.80, Uncertain significance, not provided
- S22I (p.Ser22Ile), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- S22N (p.Ser22Asn), ExAC rs759915686, gnomAD rs759915686, REVEL 0.43, CADD 24.20, Uncertain significance, Intellectual disability, autosomal dominant 52
- P23L (p.Pro23Leu), TOPMed rs908343803, gnomAD rs908343803, REVEL 0.28, CADD 23.90, Uncertain significance
- P23R (p.Pro23Arg), rs908343803, ClinGen CA30912713, ClinVar RCV001814671, TOPMed rs908343803, REVEL 0.43, CADD 23.90, Uncertain significance, not provided
- P23S (p.Pro23Ser), Ensembl rs1668884051
- S24F (p.Ser24Phe), rs2524745304, ClinGen CA342716592, ClinVar RCV003141565, NCI-TCGA TCGA novel, Uncertain significance, Intellectual disability, autosomal dominant 52
- A25V (p.Ala25Val), rs1470664170, NCI-TCGA Cosmic COSV6421, cosmic curated COSV64211, gnomAD rs1470664170, REVEL 0.29, CADD 17.50, Variant assessed as somatic; moderate impact.
- I26V (p.Ile26Val), ExAC rs751862423, TOPMed rs751862423, gnomAD rs751862423, REVEL 0.23, CADD 7.20
- S27G (p.Ser27Gly), 1000Genomes rs545408345, ExAC rs545408345, TOPMed rs545408345, gnomAD rs545408345, REVEL 0.23, CADD 15.40
- S27N (p.Ser27Asn), ExAC rs773290434, TOPMed rs773290434, gnomAD rs773290434, REVEL 0.22, CADD 0.02
- S27R (p.Ser27Arg), 1000Genomes rs545408345, ExAC rs545408345, TOPMed rs545408345, gnomAD rs545408345, REVEL 0.23, CADD 21.60
- T28A (p.Thr28Ala), TOPMed rs1441034932, gnomAD rs1441034932, REVEL 0.22, CADD 4.01
- T28I (p.Thr28Ile), cosmic curated COSV64205, TOPMed rs1428513096, gnomAD rs1428513096, REVEL 0.22, CADD 18.10
- T28S (p.Thr28Ser), TOPMed rs1428513096, gnomAD rs1428513096, REVEL 0.30, CADD 22.10
- T30S (p.Thr30Ser), ExAC rs761764613, TOPMed rs761764613, gnomAD rs761764613, REVEL 0.33, CADD 22.20, Likely benign, Inborn genetic diseases
- L31V (p.Leu31Val), ESP rs149403397, TOPMed rs149403397, gnomAD rs149403397
- V32I (p.Val32Ile), ESP rs370980279, ExAC rs370980279, TOPMed rs370980279, gnomAD rs370980279, REVEL 0.22, CADD 19.20
- S33G (p.Ser33Gly), ExAC rs772090388, gnomAD rs772090388, REVEL 0.29, CADD 15.80
- K34N (p.Lys34Asn), Ensembl rs1558188654
- K34R (p.Lys34Arg), TOPMed rs1270040737
- R35K (p.Arg35Lys), rs1340292764, ClinGen CA342716182, ClinVar RCV002841858, TOPMed rs1340292764, REVEL 0.17, CADD 20.00, Uncertain significance, Inborn genetic diseases
- R35S (p.Arg35Ser), gnomAD rs1200109119, REVEL 0.41, CADD 21.60
- V37G (p.Val37Gly), cosmic curated COSV64206
- E38D (p.Glu38Asp), rs1558188620, ClinGen CA342716113, ClinVar RCV001310872, Ensembl rs1558188620, AlphaMissense 0.08, MetaLR 0.20, Uncertain significance, not provided
- L39I (p.Leu39Ile), ExAC rs745674657, gnomAD rs745674657, REVEL 0.22, CADD 15.30
- L39V (p.Leu39Val), ExAC rs745674657, gnomAD rs745674657, REVEL 0.24, CADD 14.90
- E40G (p.Glu40Gly), ExAC rs778787049, TOPMed rs778787049, gnomAD rs778787049, REVEL 0.33, CADD 23.80
- K41N (p.Lys41Asn), NCI-TCGA Cosmic COSV6421, cosmic curated COSV64210, Variant assessed as somatic; moderate impact.
- K41R (p.Lys41Arg), ExAC rs770847441, gnomAD rs770847441, REVEL 0.12, CADD 15.90
- N42H (p.Asn42His), gnomAD rs1384072053, REVEL 0.21, CADD 11.50
- N42K (p.Asn42Lys), TOPMed rs1468050249, REVEL 0.19, CADD 17.00
- T43K (p.Thr43Lys), ExAC rs749009326, gnomAD rs749009326, REVEL 0.23, CADD 21.00
- T43R (p.Thr43Arg), ExAC rs749009326, gnomAD rs749009326, REVEL 0.24, CADD 20.50
- K44E (p.Lys44Glu), gnomAD rs1558188569, REVEL 0.26, CADD 16.30
- K44N (p.Lys44Asn), ExAC rs755691746, TOPMed rs755691746, gnomAD rs755691746, REVEL 0.30, CADD 17.70
- K44Q (p.Lys44Gln), gnomAD rs1558188569, REVEL 0.25, CADD 19.30
- E45V (p.Glu45Val), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- E46K (p.Glu46Lys), NCI-TCGA Cosmic COSV6421, cosmic curated COSV64210, REVEL 0.44, CADD 23.60, Variant assessed as somatic; moderate impact.
- E46Q (p.Glu46Gln), gnomAD rs1668877114, REVEL 0.44, CADD 23.20
- E47K (p.Glu47Lys), ExAC rs752098994, gnomAD rs752098994, REVEL 0.32, CADD 23.60
- D48Y (p.Asp48Tyr), rs2524743805, ClinGen CA342715816, ClinVar RCV003409121, REVEL 0.34, CADD 23.00, Uncertain significance, not provided
- R50C (p.Arg50Cys), ESP rs138907231, ExAC rs138907231, TOPMed rs138907231, gnomAD rs138907231, REVEL 0.21, CADD 23.10
- R50H (p.Arg50His), rs374072309, ESP rs374072309, ExAC rs374072309, TOPMed rs374072309, REVEL 0.18, CADD 16.20, Variant assessed as somatic; moderate impact.
- K51E (p.Lys51Glu), gnomAD rs1385570264, REVEL 0.19, CADD 22.60
- K51R (p.Lys51Arg), ExAC rs766785066, TOPMed rs766785066, gnomAD rs766785066, REVEL 0.29, CADD 20.90
- R52Q (p.Arg52Gln), cosmic curated COSV64207, ExAC rs750694607, TOPMed rs750694607, gnomAD rs750694607, REVEL 0.25, CADD 21.20
- R52W (p.Arg52Trp), rs199618784, ClinGen CA1147525, cosmic curated COSV64208, ClinVar RCV002641492, REVEL 0.23, CADD 21.60, Conflicting interpretations, Intellectual disability, autosomal dominant 52; Inborn genetic diseases
- N53S (p.Asn53Ser), TOPMed rs1026018290, gnomAD rs1026018290, REVEL 0.24, CADD 11.30, Uncertain significance, Inborn genetic diseases
- R54* (p.Arg54Ter), cosmic curated COSV64205
- R54P (p.Arg54Pro), rs1416735817, ClinGen CA342715600, ClinVar RCV001420514, TOPMed rs1416735817, AlphaMissense 0.25, MetaLR 0.39, Uncertain significance, Intellectual disability, autosomal dominant 52
- R54Q (p.Arg54Gln), rs1416735817, NCI-TCGA Cosmic COSV6420, cosmic curated COSV64207, TOPMed rs1416735817, REVEL 0.23, AlphaMissense 0.25, Uncertain significance
- R56K (p.Arg56Lys), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- I58V (p.Ile58Val), ExAC rs765334229, TOPMed rs765334229, gnomAD rs765334229, REVEL 0.16, CADD 1.40
- E59A (p.Glu59Ala), gnomAD rs1204718205, REVEL 0.25, CADD 11.90, Likely benign
- E59D (p.Glu59Asp), Ensembl rs767947472
- E59G (p.Glu59Gly), rs1204718205, ClinGen CA342715427, ClinVar RCV001252152, gnomAD rs1204718205, REVEL 0.25, CADD 13.40, Likely benign, Intellectual disability
- E59K (p.Glu59Lys), rs1668873954, ClinGen CA342715431, ClinVar RCV002892067, NCI-TCGA TCGA novel, REVEL 0.30, CADD 18.00, Uncertain significance, Inborn genetic diseases
- A60G (p.Ala60Gly), ExAC rs767568776, TOPMed rs767568776, gnomAD rs767568776, REVEL 0.29, CADD 20.50, Uncertain significance
- A60T (p.Ala60Thr), gnomAD rs1360448953, REVEL 0.20, CADD 0.13
- A60V (p.Ala60Val), rs767568776, ClinGen CA1147521, ClinVar RCV003404861, ClinVar RCV004364470, REVEL 0.21, CADD 16.70, Uncertain significance, not specified; Inborn genetic diseases
- G61R (p.Gly61Arg), TOPMed rs1244265447, gnomAD rs1244265447, REVEL 0.35, CADD 21.50
- G61V (p.Gly61Val), cosmic curated COSV64213
- G61W (p.Gly61Trp), TOPMed rs1244265447, gnomAD rs1244265447, REVEL 0.43, CADD 23.70
- K62E (p.Lys62Glu), NCI-TCGA Cosmic COSV6420, cosmic curated COSV64206, Ensembl rs1571053168, Variant assessed as somatic; moderate impact.
- D63G (p.Asp63Gly), TOPMed rs1430820734, gnomAD rs1430820734, REVEL 0.22, CADD 18.90, Conflicting interpretations, not provided; Inborn genetic diseases
- D63Y (p.Asp63Tyr), NCI-TCGA TCGA novel, REVEL 0.19, CADD 22.80, Variant assessed as somatic; moderate impact.
- D64N (p.Asp64Asn), NCI-TCGA Cosmic COSV6421, cosmic curated COSV64214, Uncertain significance, not provided
- G65D (p.Gly65Asp), ESP rs147025395, ExAC rs147025395, gnomAD rs147025395, REVEL 0.28, CADD 21.00
- G65V (p.Gly65Val), ESP rs147025395, ExAC rs147025395, gnomAD rs147025395
- T67A (p.Thr67Ala), TOPMed rs1252120318, gnomAD rs1252120318, REVEL 0.31, CADD 15.50, Uncertain significance, ASH1L-related disorder
- T67S (p.Thr67Ser), rs2524742577, ClinGen CA342715178, ClinVar RCV003059974, Uncertain significance, not provided
- D68E (p.Asp68Glu), 1000Genomes rs201153025, ExAC rs201153025, TOPMed rs201153025, gnomAD rs201153025, REVEL 0.24, CADD 18.20
- A69E (p.Ala69Glu), Ensembl rs1668870901, REVEL 0.29, CADD 22.80
- A69S (p.Ala69Ser), TOPMed rs1418644741, gnomAD rs1418644741, REVEL 0.33, CADD 24.20
- A69V (p.Ala69Val), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- Q70H (p.Gln70His), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- Q70R (p.Gln70Arg), ESP rs142234064, ExAC rs142234064, TOPMed rs142234064, gnomAD rs142234064, REVEL 0.43, CADD 25.40
- Q71R (p.Gln71Arg), TOPMed rs1334445031, gnomAD rs1334445031, REVEL 0.37, CADD 23.10
- Q72R (p.Gln72Arg), 1000Genomes rs146475561, ESP rs146475561, ExAC rs146475561, TOPMed rs146475561, REVEL 0.48, CADD 24.80
- S74L (p.Ser74Leu), rs769272721, ClinGen CA1147514, ClinVar RCV003141575, ExAC rs769272721, REVEL 0.57, CADD 26.60, Conflicting interpretations, Intellectual disability, autosomal dominant 52
- V75A (p.Val75Ala), NCI-TCGA Cosmic COSV6421, cosmic curated COSV64211, Variant assessed as somatic; moderate impact.
- E77* (p.Glu77Ter), NCI-TCGA Cosmic COSV6420, cosmic curated COSV64205, CADD 36.00, Variant assessed as somatic; high impact.
- T78A (p.Thr78Ala), 1000Genomes rs201975309, REVEL 0.31, CADD 21.00
- T78K (p.Thr78Lys), rs2524741917, ClinGen CA342714801, ClinVar RCV004527879, Uncertain significance, ASH1L-related disorder
- N79D (p.Asn79Asp), ExAC rs747697097, gnomAD rs747697097, REVEL 0.39, CADD 24.20
- N79Y (p.Asn79Tyr), ExAC rs747697097, gnomAD rs747697097, REVEL 0.47, CADD 26.40
- E82K (p.Glu82Lys), Ensembl rs1571052988, REVEL 0.62, CADD 26.10
- G83E (p.Gly83Glu), cosmic curated COSV10529
- G83R (p.Gly83Arg), cosmic curated COSV10468, REVEL 0.67, CADD 25.20
- N84K (p.Asn84Lys), rs754468135, ClinGen CA1147511, ClinVar RCV004420722, ExAC rs754468135, REVEL 0.40, CADD 20.90, Uncertain significance, Inborn genetic diseases
- N84S (p.Asn84Ser), rs1668868551, ClinGen CA342714561, ClinVar RCV001329679, Ensembl rs1668868551, AlphaMissense 0.20, MetaLR 0.18, Uncertain significance, Intellectual disability, autosomal dominant 52
- L85I (p.Leu85Ile), rs2524741504, ClinGen CA342714554, ClinVar RCV002288056, Uncertain significance, not provided
- L87F (p.Leu87Phe), cosmic curated COSV10529, ExAC rs747561358, TOPMed rs747561358, gnomAD rs747561358, REVEL 0.55, CADD 23.80, Likely benign, not provided
- L87V (p.Leu87Val), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- K88T (p.Lys88Thr), cosmic curated COSV10529
- I89F (p.Ile89Phe), gnomAD rs1240366273, REVEL 0.55, CADD 26.60
- I89V (p.Ile89Val), gnomAD rs1240366273, REVEL 0.47, CADD 24.70
- A93G (p.Ala93Gly), NCI-TCGA Cosmic COSV6421, cosmic curated COSV64214, Variant assessed as somatic; moderate impact.
- A93V (p.Ala93Val), Ensembl rs1001928178, REVEL 0.52, CADD 27.00
- R95I (p.Arg95Ile), NCI-TCGA Cosmic COSV1008, cosmic curated COSV10085, Ensembl rs2148843211, Variant assessed as somatic; moderate impact.
- K97E (p.Lys97Glu), TOPMed rs1668866329, gnomAD rs1668866329, REVEL 0.57, CADD 27.20
- K98N (p.Lys98Asn), rs867966554, ClinGen CA342714147, ClinVar RCV003149420, gnomAD rs867966554, REVEL 0.54, CADD 23.40, Uncertain significance, not provided
- K98T (p.Lys98Thr), cosmic curated COSV10819
- P99L (p.Pro99Leu), NCI-TCGA Cosmic COSV6420, cosmic curated COSV64205, Variant assessed as somatic; moderate impact.
- P100Q (p.Pro100Gln), Ensembl rs1018885108, REVEL 0.60, CADD 25.40
- P100S (p.Pro100Ser), cosmic curated COSV64211
- K101N (p.Lys101Asn), cosmic curated COSV10819
- K101R (p.Lys101Arg), rs1668865625, ClinGen CA342714029, ClinVar RCV003332864, ClinVar RCV005485385, AlphaMissense 0.33, MetaLR 0.84, Uncertain significance, Inborn genetic diseases; not provided
- N102D (p.Asn102Asp), TOPMed rs1359259334, gnomAD rs1359259334, REVEL 0.37, CADD 25.70
- N102S (p.Asn102Ser), ExAC rs750707815, gnomAD rs750707815, REVEL 0.34, CADD 22.80
- N102T (p.Asn102Thr), ExAC rs750707815, gnomAD rs750707815, REVEL 0.38, CADD 23.50
- E104K (p.Glu104Lys), Ensembl rs2148843108
- N105K (p.Asn105Lys), gnomAD rs1360495431, REVEL 0.52, CADD 23.50
- C108R (p.Cys108Arg), rs2148843074, ClinGen CA342713647, ClinVar RCV001759068, Ensembl rs2148843074, AlphaMissense 1.00, MetaLR 0.91, Uncertain significance, not provided
- R109* (p.Arg109Ter), NCI-TCGA TCGA novel, Ensembl rs2148843055, Variant assessed as somatic; high impact.
- R109P (p.Arg109Pro), ExAC rs757357705, gnomAD rs757357705, REVEL 0.39, CADD 22.40, Likely pathogenic
- R109Q (p.Arg109Gln), rs757357705, ClinGen CA342713603, ClinVar RCV003331798, ExAC rs757357705, REVEL 0.43, CADD 25.60, Conflicting interpretations, Intellectual disability, autosomal dominant 52
- P110L (p.Pro110Leu), Ensembl rs2148843013, REVEL 0.75, CADD 27.30
- P110S (p.Pro110Ser), Ensembl rs2148843020
- A111T (p.Ala111Thr), Ensembl rs2148843001
- I112V (p.Ile112Val), ExAC rs764329610, TOPMed rs764329610, gnomAD rs764329610, REVEL 0.34, CADD 23.90
- T114A (p.Thr114Ala), TOPMed rs1475364657, REVEL 0.25, CADD 20.50
- T114I (p.Thr114Ile), Ensembl rs2148842973, REVEL 0.35, CADD 21.60
- T115N (p.Thr115Asn), cosmic curated COSV10611
- I116T (p.Ile116Thr), rs111605066, ClinGen CA1147502, ClinVar RCV000883023, ClinVar RCV004530918, REVEL 0.33, CADD 20.70, Benign, not provided
- K117E (p.Lys117Glu), cosmic curated COSV64209
- K117R (p.Lys117Arg), gnomAD rs1170887213, REVEL 0.31, CADD 19.10
- H118Y (p.His118Tyr), Ensembl rs2148842909
- P119R (p.Pro119Arg), rs375367640, ClinGen CA1147500, ClinVar RCV004420728, ClinVar RCV004723581, REVEL 0.43, CADD 23.40, Uncertain significance, Intellectual disability, autosomal dominant 52; Inborn genetic diseases
- P119S (p.Pro119Ser), NCI-TCGA Cosmic COSV6420, Variant assessed as somatic; moderate impact.
- P119T (p.Pro119Thr), cosmic curated COSV64209
- R120K (p.Arg120Lys), ExAC rs762819058
- R120M (p.Arg120Met), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- K121N (p.Lys121Asn), cosmic curated COSV64213, REVEL 0.30, CADD 23.00
- G126E (p.Gly126Glu), TOPMed rs1421832262, gnomAD rs1421832262, REVEL 0.45, CADD 23.30
- K127N (p.Lys127Asn), NCI-TCGA TCGA novel, REVEL 0.35, CADD 22.70, Variant assessed as somatic; moderate impact.
- K127R (p.Lys127Arg), Ensembl rs1668859350, REVEL 0.30, CADD 23.20
- M128T (p.Met128Thr), NCI-TCGA Cosmic COSV1008, cosmic curated COSV10085, Variant assessed as somatic; moderate impact.
- T129M (p.Thr129Met), ExAC rs772816032, TOPMed rs772816032, gnomAD rs772816032, REVEL 0.33, CADD 24.60
- D130G (p.Asp130Gly), gnomAD rs1197609630, REVEL 0.27, CADD 21.90, Uncertain significance, not provided
- D130N (p.Asp130Asn), Ensembl rs2148842779, REVEL 0.38, CADD 23.00
- E131K (p.Glu131Lys), Ensembl rs1668857770
- K132R (p.Lys132Arg), TOPMed rs1334010226, gnomAD rs1334010226, REVEL 0.33, CADD 24.70
- N133S (p.Asn133Ser), rs1238441171, ClinGen CA342712767, cosmic curated COSV64211, ClinVar RCV002472226, REVEL 0.35, CADD 15.80, Uncertain significance, Intellectual disability, autosomal dominant 52
- C136S (p.Cys136Ser), rs1233740479, ClinGen CA342712619, ClinVar RCV002471743, TOPMed rs1233740479, REVEL 0.30, CADD 19.50, Uncertain significance, Intellectual disability, autosomal dominant 52
- P137S (p.Pro137Ser), ExAC rs747812661, TOPMed rs747812661, gnomAD rs747812661, REVEL 0.21, CADD 16.60
- S138* (p.Ser138Ter), cosmic curated COSV10970
- S138P (p.Ser138Pro), Ensembl rs2148842680, REVEL 0.37, CADD 24.70
- R140* (p.Arg140Ter), ExAC rs776241230, TOPMed rs776241230, gnomAD rs776241230
- R140L (p.Arg140Leu), ESP rs368390442, ExAC rs368390442, TOPMed rs368390442, gnomAD rs368390442, REVEL 0.25, CADD 24.80, Likely benign, not provided
- R140Q (p.Arg140Gln), cosmic curated COSV64211, ESP rs368390442, ExAC rs368390442, TOPMed rs368390442, REVEL 0.23, CADD 21.10, Uncertain significance, Inborn genetic diseases
- P142T (p.Pro142Thr), ExAC rs760195651, TOPMed rs760195651, gnomAD rs760195651, REVEL 0.20, CADD 20.90, Uncertain significance, not provided
- L145S (p.Leu145Ser), cosmic curated COSV10085
- Y146C (p.Tyr146Cys), rs546762132, ClinGen CA1147470, ClinVar RCV000994128, 1000Genomes rs546762132, REVEL 0.33, CADD 23.60, Uncertain significance, not provided
- Y146N (p.Tyr146Asn), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- D150N (p.Asp150Asn), NCI-TCGA TCGA novel, REVEL 0.26, CADD 21.80, Variant assessed as somatic; moderate impact.
- D150V (p.Asp150Val), ExAC rs746423268, gnomAD rs746423268, REVEL 0.29, CADD 22.80
- D151G (p.Asp151Gly), ExAC rs779454818, gnomAD rs779454818
Public ASH1L analysis runs
- ASH1L analysis run — ASH1L (3,636 variants) — completed 2026-08-20